CAJ | 학술논문

异基因造血干细胞移植是治愈血液系统恶性疾病的唯一治疗手段，但常因难以获得人类白细胞抗原(human leukocyte antigen，HLA)相合的造血干细胞而受到限制。脐血含有丰富的造血干细胞，可作为造血干细胞移植的干细胞来源。它具有实物冻存、应用方便以及移植物抗宿主病较轻等优点。近年来，应用脐血移植成功地治疗恶性血液肿瘤的报道愈来愈多，脐血移植的基础研究也获得了较大的进步。现就脐血移植的应用现状、研究进展以及如何选择合适的脐血作一综述。
이기인조혈간세포이식시치유혈액계통악성질병적유일치료수단，단상인난이획득인류백세포항원(human leukocyte antigen，HLA)상합적조혈간세포이수도한제。제혈함유봉부적조혈간세포，가작위조혈간세포이식적간세포래원。타구유실물동존、응용방편이급이식물항숙주병교경등우점。근년래，응용제혈이식성공지치료악성혈액종류적보도유래유다，제혈이식적기출연구야획득료교대적진보。현취제혈이식적응용현상、연구진전이급여하선택합괄적제혈작일종술。
Allogeneic hematopoietic stem cell transplantation is the only treatment method to cure hemato-logic malignancies. However, dififculty in obtaining the human leukocyte antigen (HLA) match donors is a major lim-itation in this therapeutic strategy. Many studies have demonstrated that umbilical cord blood is rich in hematopoietic stem cells and can be used as a source of stem cells of hematopoietic stem cell transplantation. Growing evidence also supports the efifcacy of cord blood transplantation (CBT) to treat patients with haematological malignancies, and the number of CBTs is rapidly increasing. Compared to other sources of stem cells, umbilical cord blood is physical cryo-preserved. Therefore, it is very convenient for transplantation, particular for those who need to receive transplantation sooner. In addition, the incidence and severity of graft versus host disease(GVHD) in CBT are usually relatively lower. Herein, we review considerations regarding status, research progresses and selection of umbilical cord blood in CBT.